Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 12/20 | 0.46 |
| ▸ | DRD3 | P35462 | 9/20 | 0.46 |
| ▸ | HTR1D | P28221 | 2/20 | 0.46 |
| ▸ | DRD4 | P21917 | 6/20 | 0.41 |
| ▸ | DRD1 | P21728 | 4/20 | 0.41 |
| ▸ | DRD5 | P21918 | 4/20 | 0.41 |
| ▸ | HTR5A | P47898 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7910926 | 0.77 | ADRA2A (0.49) | DRD2DRD3DRD1DRD5S1PR1 | |
| SCHEMBL7930810 | 0.76 | DRD2 (0.46) | DRD2DRD3HTR1DDRD4DRD1 | |
| SCHEMBL30042062 | 0.75 | DRD2 (0.55) | DRD2DRD3HTR1DDRD4DRD1 | |
| SCHEMBL1820878 | 0.73 | DRD2 (0.53) | DRD2DRD3HTR1DDRD4DRD1 | |
| SCHEMBL3113928 | 0.73 | DRD2 (0.53) | DRD2DRD3HTR1DDRD4DRD1 | |
| SCHEMBL11960176 | 0.73 | DRD2 (0.48) | DRD2DRD3HTR1DDRD4DRD1 | |
| SCHEMBL17747376 | 0.72 | DRD2 (0.44) | DRD2DRD3HTR1DDRD4DRD1 | |
| SCHEMBL8648724 | 0.70 | ADRA2A (0.47) | S1PR1KCNH2 | |
| SCHEMBL7917428 | 0.70 | HTR1A (0.38) | S1PR1KCNH2 | |
| SCHEMBL2589591 | 0.70 | DRD2 (0.50) | DRD2DRD3HTR1DDRD4DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010042473-A1 | BIARYL SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS | SCHERING CORPORATION (US) | 2010-04-15 | — | — | WO | disclosed |